Conversation with an A-Player

Start a Conversation with Bob!

Bob Weber, MBA, has been a Managing Director with Next Stage Solutions, Inc. since 2012. Possessing extensive financial management experience, Bob is a global financial executive with over 40 years of Commercial and Operational Finance experience in the Life Science space, primarily within the MedTech and Pharmaceutical companies of healthcare giant Johnson & Johnson. In addition, he has been Director of Business Development for the J&J Orthopaedic Company; Vice President of Finance and Executive Committee member for a foreign based, privately owned Medical Diagnostic company; and been responsible for financial operations in the US, Canada, and the UK.

Over his career, Bob has assisted Company Leadership as business advisor in the development and execution of business strategies to support company growth objectives. These activities have ranged from new product evaluations/commercialization; negotiation of strategic business alliances; and implementation of critical business systems.


We are proud to present a sample of his accomplishments for both NSS and other organizations:

  • Participated in the worldwide commercialization of over 20 new products in highly regulated industries with combined revenue in excess of $500 Mil in annual sales.
  • Led development of formal strategic planning process for two $175 Mil worldwide business franchises with strategic goals, divisional objectives, and interactive financial planning capabilities.
  • Conducted comprehensive financial and business analysis that reduced manufacturing structure from nine facilities to three centers of excellence avoiding $2.5 Mil in consolidation costs.
  • Led pricing negotiations that shifted $5 Mil in profit margin from strategic business partner to company, while resetting the pricing matrix agreement for our future relationship.
  • Directed implementation of Activity-Based Management and developed operations performance measures for 7 manufacturing plants saving millions in cost reductions and elimination of non-value added expenses.
  • Negotiated numerous New Business Development agreements (distribution, licensing, and supply agreements) with annual sales in excess of $20 Mil.
  • Organized and led highly successful CFO searches for midmarket companies in expansion mode.

Are you looking at growth differently, or what we call nonlinear growth?  Bob is easy going and the guy to talk to.  He will be delighted to start a conversation with you.

Email Bob at or

call 617-449-7728

Growth Strategy I

in collaboration with

ceo breakfast series on growth strategies for small to mid-cap ($10-$100MM)  companies in the MedTech industry


Wednesday, 14 January 2015

7:30am—9:30am | Constant Contact | 1601 Trapelo Road | Waltham

by personal invitation only | registration


Gordon Craig, CEO of Sterngold Dental LLC

which is the union of two strong companies with impressive dental histories: APM-Sterngold and ImplaMed. Sterngold was founded in 1897 as a fabricator of precious alloys, and is credited as among the first to produce consistently formulated and alloyed dental casting golds.

Jeffrey Thumm, CEO of Albright Technologies

which is your fastest source for long and short term implantable medical silicone molded parts. We specialize in manufacturing prototype and low volume production silicone components with a specific focus on quality, delivery, and innovation. With our extensive silicone molding experience we can help you with medical silicone material selection and design for manufacturability.

Discussion Leaders:

Dick O’Brien, Past President MDG, Principal, Nagog Hill Partners

Rudi Scheiber-Kurtz, CEO, Next Stage Sol

Bob Weber, Managing Director, Next Stage Solutions

Who should Attend: CEOs, Business Owners, CFOs, COOs and Board Members

In this first of a 3-part Breakfast Series we will be addressing challenges and opportunities of mid-market MedTech companies to achieve profit-able growth.

The discussions will include how and why to make an acquisition or enter a partnership agreement. The topic will be approached from different points of view provided by the experts and will look at the “Business of doing Business”. This holistic approach will include the Technical as well as the Human Capital side in the dialogue.

Growth Strategy  II | Product & Market Diversification | April 16

Growth Strategy III | Scalability Issues | June 10

For more information: Bob Weber 617-449-7728 | Next Stage Solutions, Inc

67 South Bedford Street, Suite 400 West, Burlington, MA 01803

NEXT STAGE SOLUTIONS, INC. | 617- 449-7728

Developing Medical Devices For Children: Opportunities & Challenges

MDG October 2013 Forum:

Developing Medical Devices For Children: Opportunities & Challenges

This program will be at Children’s Hospital, Boston. Cutoff for preregistration is 6 p.m. Oct. 7


The development of medical devices for children has greatly lagged behind the development of devices for adults. The label “child” covers such diverse periods of human growth — from newborn to age 17 — that it creates a segmented and tiny market for device makers. Technical barriers challenge engineers to develop products for rapidly changing bodies. Implanted rigid devices do not grow with the child. And unless devices are designed with exquisite consciousness of child behavior, safety and patient compliance may be extremely difficult to attain.

Despite these challenges, some companies have succeeded in small, niche markets. There also are opportunities for incredible engineering accomplishments in solving health care needs. While the FDA has set up incentives for developing child age-specific pharmaceuticals, there is no similar program for medical devices.

Our October program will feature a panel of experts discussing the economic gaps, will examine some of the unique engineering hurdles and will look at one model for addressing some of these challenges.


  • Don Lombardi, CEO, Institute for Pediatric Innovation
  • Aaron Sandoski, Managing Director, Norwich Ventures
  • George Kenney, President, EntraTympanic
Lombardi Lombardi Lombardi
Lombardi Sandoski Kenney

Who Should Attend:

  • Entrepreneurs with a commitment to improving the lives of sick children
  • Engineers ready for a challenge to current ways of conceiving and designing products
  • Small and medium size medical device product development teams eager to cultivate new ground in the industry
  • Parents seeking answers to the heretofore insoluble problems of getting therapies that work for young bodies and minds
  • Clinicians hungry for alternatives to jerry-rigging oversize adult devices for small children
  • Anyone with an interest in how life sciences can effectively turn its attention to creating to previously intractable problems in serving some of the most vulnerable among us

About MDG

The Medical Development Group (MDG) is a community of individuals professionally committed to the Medical Device and other Medical Technology Industry segments united by the belief that innovation and advances in technology lead to substantial improvements in health care. MDG pursues this mission through the organization of educational programs and forums: the facilitation of cross-disciplinary dialogue and collaboration; the creation of venues for networking and information sharing for current and aspiring professionals, clinicians, and entrepreneurs; and the development of alliances with complementary organizations.



Combination Products – A Strategic Inflection

Key Highlights and Takeaways by Bob M. Weber, Managing Director of MedTech at Next Stage Solutions, Inc. |

Addressing the complexities of clinical challenges in the future, an increasing number of newly developed medical devices will be used in conjunction with pharmaceutical and biologic products to create “combination products”.  These combination products are designated as a special class of products within the FDA. The current and future regulatory and market challenges of introducing combination products were discussed by a group of distinguished speakers including former FDA commissioner Dr. Andrew Von Eschenbach.

Below are some key highlights and takeaways from the various presentations from the recent MDG Seminar “Addressing the Challenges of Combination Products, Moving to Interoperable Solutions” at the Lahey Clinic in Burlington, MA.

· A strategic inflection in the Life Sciences area is happening NOW! Such a change that you will not recognize it.  We have moved from observing manifestations to understanding mechanisms.  This is the Strategic Inflection.

· The Process – Discovery, Development, Delivery |  The Product – Integrated Interoperable Solutions

· Discovery, Development, Delivery is no longer linear but circular.  Need to integrate them more seamlessly.

· Speed = Success |  Coordinate Financial Resources, Intellectual Capital, and Infrastructure

· Need collaborative efforts between Financial Investors, Academia, Industry, and Government

· MDG can play a leadership role in driving change. They can be the Int

· Changes in Discovery – team approach, emphasis on milestones and outcomes, new fields

· Changes in Development – shift from “components” to “solutions”; collaboration and share of IP (Intellectual Property) at the outset; new business model for ROI (Return on Investment)

· Changes in Delivery – New Systems ; Advanced Technologies; New Regulatory Policies & Practices

· Important: Product has “value” to the patient/customer if it is a solution to their problem.

· For an Integrated Interoperable Solution, there will be a need for: sharing of cost, profit, and recognition; new valuation models for component pricing; market based vs. government imposed regulations.

· The game has changed from “Golf” to “Basketball” (not track & field). Performance of the team will determines success.

· The path for combination products has many challenges: technical (collaborators don’t speak the same language); Regulatory; Reimbursement Issues; Health Economic Outcomes; Marketing Regulations for promoting products.

· Pricing could be key: Cost of Alternative +  Your Unique Value Proposition – Cost of New Product = Difference in price premium of New Products.

· Healthcare Economics will look at the relationship of cost (lower to higher) and effect (better to worst).

· There will be a need to realign the benefits to all stakeholders in order to get a benefit for all – Physicians, Facilities, and payers.

· Value will be defined in terms of time:    Shorter timeframes – lower admissions, lower re = admissions (30 – 90 days).  Medium timeframes – fewer revisions, removals, reductions.  Long-term timeframes –  disease redemption, resource reduction